Breaking News, Collaborations & Alliances

Novo Nordisk Foundation, CARB-X Partner on Drug-Resistant Infections

Aims to advance ideas for cutting-edge antibacterial products from basic research to clinical development.

The Novo Nordisk Foundation is committing $25 million to support the early-stage development of innovative tools to prevent, diagnose and treat the most dangerous drug-resistant bacterial infections. The three-year grant will go to the combating antibiotic-resistant bacteria Biopharmaceutical Accelerator (CARB-X). CARB-X, a global non-profit partnership funded by four G7 governments and three of the world’s biggest foundations, provides support to these product developers. The partnersh...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters